The following speakers have received an honorarium from Novo Nordisk for their input to and facilitation of this educational material:
- Prof. Aleksander Krag, University of Southern Denmark, Odense University Hospital, Denmark
- Prof. Geltrude Mingrone, King’s College London, UK, and Università Cattolica del S. Cuore, Italy
1. Kasper P, et al. Clin Res Cardiol. 2021;110:921–937
2. Muzurović E, et al. Hypertension. 2022;79:1319–1326
- To improve understanding of the risk factors and comorbidities for MASLD/MASH, and specifically the link between CV and MASLD
- To raise awareness of adverse outcomes of MASLD/MASH, including hepatic and non-hepatic consequences of unchecked disease progression
- To discuss optimal multidisciplinary collaboration between endocrinology, cardiology, primary care and hepatology to improve care of people with MASLD/MASH
